Hallux Valgus Clinical Trial
Official title:
A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy Followed by a Voluntary Open-Label Extension
The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of 3 different dose levels of CG5503 compared with oxycodone and with placebo in patients who have had a bunionectomy, and to assess the safety of the drug for 9 days after patients are discharged from the hospital.
Patients undergoing bunionectomy often experience moderate to severe acute pain post-surgery. Normally such pain is controlled when patients receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. CG5503, a newly synthesized drug also acts as a centrally acting analgesic but has a dual mode of action. The aim of this study is to investigate the effectiveness (level of pain control) and safety (side effects) of 3 dose levels of CG5503 Immediate Release (IR) compared to no drug (placebo) or one dose level of oxycodone (an opioid commonly used to treat post-surgical pain). This study is a randomized (patients are assigned different treatments based on chance), double-blind (neither investigator nor patient will know which treatment is received), active- and placebo-controlled, parallel-group, multicenter study to evaluate treatment of the acute pain from bunionectomy. The study will include a blinded 72 hour inpatient phase immediately following bunionectomy, during which patients will be treated with either 50-, 75-, or 100-mg CG5503 IR base, a placebo, or 15-mg oxycodone IR, and pain intensity and pain relief will be periodically assessed. Following this phase, patients wishing to continue treatment with CG5503 IR may enter an outpatient voluntary nonrandomized, open-label extension phase for 9 days when they will receive 50- or 100-mg CG5503 IR. Assessments of pain relief include the pain intensity numeric rating scale (PI), pain relief numeric rating scale (PAR), and patient global impression of change scale (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples will be collected for the determination of serum concentrations of CG5503 and oxycodone. The null hypothesis for the study is that efficacy results for all CG5503 IR dosage groups are equal to placebo based on the mean sum of pain intensity difference at 48 hours. The alternative study hypothesis is that at least 1 dose strength of CG5503 will be different from placebo in controlling pain at 48 hours. CG5503 IR 50, or 75, or 100 mg (of the base), or oxycodone 15 mg, or placebo: 1 capsule taken every 4 to 6 hours during the 72-hour postsurgery phase of the study; and CG5503, 50 mg capsules, 1 to 2 tablets taken by mouth every 4 to 6 hours for up to 9 days during the open label portion of the study. All doses of study treatment will be taken with approximately 120 mL of water with or without food. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04473196 -
The Effect of Weight Bearing on Patient Outcomes Following 1st MTP Joint Fusion
|
N/A | |
Recruiting |
NCT05587569 -
Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)
|
N/A | |
Recruiting |
NCT05555459 -
Performance and Safety Evaluation of Inion CompressOn Screw in Foot and Ankle Surgeries. PMCF Investigation
|
N/A | |
Completed |
NCT02121119 -
Lidocaine Versus Bupivacaine in Ambulatory Continuous Block With Elastomeric Pump
|
Phase 4 | |
Enrolling by invitation |
NCT00600899 -
Home Infusors for Analgesia After Foot Surgery
|
Phase 4 | |
Completed |
NCT05579054 -
Translation, Validity, and Reliability of the Foot Posture Index (FPI-6) - Turkish Version
|
||
Terminated |
NCT05082012 -
Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D)
|
N/A | |
Recruiting |
NCT05051709 -
Can Hypermobility of First Ray Affect Surgical Treatment of Hallux Valgus
|
N/A | |
Recruiting |
NCT04716140 -
Prospective Study: The Effect on Clinical Outcome After Treatment of MTP Cartilage Lesions in Hallux Valgus Surgery
|
N/A | |
Active, not recruiting |
NCT04145882 -
Efficacy of Additional Osteotomies to Correct Hallux Valgus
|
N/A | |
Completed |
NCT04468555 -
Hallux Valgus Manual Therapy Based on Global Postural Reeducation.
|
N/A | |
Terminated |
NCT03257540 -
Early Weight-Bearing After Lapidus Arthrodesis
|
||
Completed |
NCT03846687 -
Validation of Patient Reported Outcome Measures for Use in Hallux Valgus
|
||
Completed |
NCT04365712 -
Osteotomy of the 1st Metatarsal for Hallux Valgus Using Pneumatic Oscillating Saw or Piezoelectric Scalpel
|
N/A | |
Recruiting |
NCT02282956 -
Ultrasound Guided Single Shot Block of Posterior Tibial Nerve for Postoperative Pain Relief After Hallux Valgus Surgery
|
Phase 4 | |
Withdrawn |
NCT01555216 -
Continuous Tibial Nerve Block Versus Single Shot Tibial Nerve Block
|
N/A | |
Completed |
NCT00683137 -
Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery
|
Phase 3 | |
Terminated |
NCT04103814 -
Effect of Topical CBD Cream for Degenerative Hallux Disorders
|
Phase 2/Phase 3 | |
Completed |
NCT03423498 -
The Toe-spread-out Exercise in Patients With Hallux Valgus and Without the Deformity
|
N/A | |
Not yet recruiting |
NCT06076655 -
Hallux Valgus Treatment Developed for Children With Cerebral Palsy
|
N/A |